Summary
- Shattuck Labs has filed to raise development capital in a U.S. IPO.
- The firm is advancing drug treatment candidates for various cancer conditions.
- STTK has shown promising early trial results and has a strong collaboration partner in Takeda Pharmaceuticals.
- Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
Shattuck Labs (STTK) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement.
The firm is a clinical stage biopharma advancing programs to treat ovarian cancer and other cancers.
STTK has produced intriguing early stage safety and efficacy results. I’ll provide a final opinion when we learn more about the IPO from management.
Company & Technology
Austin, Texas-based Shattuck was founded to develop drugs that simultaneously inhibit checkpoints in various cancers while bolstering the body's immune response and ability to act against tumors.
Management is headed by co-founder and CEO Taylor Schreiber, M.D., Ph.D, who was previously Vice President of R&D and Chief Scientific Officer at Heat Biologics.
Below is a brief overview video of the warning signs of ovarian cancer:
